HR2 haplotype in Arab population and patients with venous thrombosis in Kuwait

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 7, 2005, Pages 1467-1471

  Jadaon, Mehrez M ^a,b   Dashti, A A R ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b NONE   (Kuwait)

Author keywords

Arab patients; HR2 haplotype; Polymerase chain reaction; Restriction fragment length polymorphism; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5;

AGAR GEL ELECTROPHORESIS; ARAB; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HAPLOTYPE; HUMAN; KUWAIT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; VENOUS THROMBOEMBOLISM; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; RISK; VEIN THROMBOSIS;

ARABS; CASE-CONTROL STUDIES; ELECTROPHORESIS, AGAR GEL; FACTOR V; FEMALE; HAPLOTYPES; HETEROZYGOTE; HUMANS; KUWAIT; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK; RISK FACTORS; VENOUS THROMBOSIS;

EID: 25144466083     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01326.x     Document Type: Article

References (31)

1. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenetic factor in venous thromboembolism. Blood 1995; 85: 607-14.
2. Perry DJ, Pasi KJ. Resistance to activated protein C and factor V Leiden. Q J Med 1997; 90: 379-85.
3. Florell SR, Rodgers GM. Inherited thrombotic disorders: an update. Am J Hematol 1997; 54: 53-60.
4. Koeleman BPC, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997; 34: 256-64.
5. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde HD, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
6. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the pro thrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
7. Adcock DM, Fink L, Marlar RA. A laboratory approach to the evaluation of hereditary hypercoagulability. Am J Clin Pathol 1997; 108: 434-49.
8. Lunghi B, Lacoviello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996; 75: 45-8.
9. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
10. Castoldi E, Rosing J, Girelli D, Hoekema L, Lunghi B, Mingozzi F, Ferraresi P, Friso S, Corrocher R, Tans G, Bernardi F. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000; 83: 362-5.
11. Alhenc-Gelas M, Nicaud V, Gandrille S, van Dreden P, Amiral J, Aubry ML, Fiessinger JN, Emmerich J, Aiach M. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999; 81: 193-7.
12. Castaman G, Faioni EM, Tosetto A, Bernardi F. The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. Haematologica 2003; 88: 1182-9.
13. Faioni EM, Castaman G, Asti D, Lussana F, Rodeghiero F. Association of factor V deficiency with factor V HR2. Haematologica 2004; 89: 195-200.
14. Pecheniuk NM, Morris CP, Walsh TP, Marsh NA. The factor V HR2 haplotype: prevalence and association of the A4070G and A6755G polymorphisms. Blood Coagul Fibrinolysis 2001; 12: 201-6.
15. Margaglione M, Bossone A, Coalizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di MG. FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile. Thromb Haemost 2002; 87: 32-6.
16. Castaman G, Lunghi B, Missiaglia E, Bernardi F, Rodeghiero F. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V. Br J Haematol 1997; 99: 257-61.
17. Faioni EM, Franchi F, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Finazzi G, Mannucci PM. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999; 94: 3062-6.
18. Luddington R, Jackson A, Pannerselvam S, Brown K, Baglin T. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost 2000; 83: 204-8.
19. de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000; 83: 577-82.
20. Kostka H, Schwarz T, Schellong S, Mix C, Kuhlisch E, Temelkova- Kurktschiev T, Henkel E, Kohler C, Gehrisch S, Siegert G. Coagulation factor V G allele and HR2 haplotype: factor V activity, activated protein C resistance and risk of venous thrombosis. Blood Coagul Fibrinolysis 2003; 14: 49-56.
21. Faioni EM. Factor V HR2: an ancient haplotype out of Africa - reasons for being interested. Thromb Haemost 2000; 83: 358-9.
22. Thorelli E, Kaufmean RJ, Dahkbäck B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998; 273: 16140-5.
23. Doggen CJ, de Visser MC, Vos HL, Bertina RM, Cats VM, Rosendaal FR. The HR2 haplotype of factor V is not associated with the risk of myocardial infarction. Thromb Haemost 2000; 84: 815-8.
24. Lecumberri R, Ceberio I, Montes R, Lopez ML, Alberca I, Rocha E. Evaluation of the factor V HR2 haplotype as a risk factor for ischemic cerebrovascular disease. Haematologica 2003; 88: 236-7.
25. Yanqing H, Fangping C, Qinzhi X, Zaifu J, Guangping W, Xiaoxia Z, Xiaoqun P, Xiaobo H. No association between thrombosis and factor V gene polymorphisms in Chinese Han population. Thromb Haemost 2003; 89: 446-51.
26. Mohanty D, al Hassan H, Neglen P, Eklof BO, Das KC. Protein C deficiency in Kuwait. J Lab Clin Med 1995; 126: 373-6.
27. Mohanty D, Das KC, al Hassan H, Neglen P, Eklof BO, Marouf R, Khamis A, al-Majidi M. Thrombophilia in ethnic Arabs in Kuwait. Ann Haematol 1996; 73: 283-90.
28. Jadaon MM, Easow SK, Kurian ES, Marouf R, Khamis A, Al-Majidi M, Das KC. A study of factor V mutation (arginine 506 → glutamin) and activated protein C resistance in patients with venous thrombosis in Kuwait. MSc Thesis. Kuwait University: Department of Pathology, Faculty of Medicine, 1998.
29. Al-Otaibi MA, Jadaon MM, Easow SK, Arya R, Marouf R, Al-Humood S, Das KC. Prothrombin G20210A mutation as a risk factor in venous thrombosis in Kuwait. MSc Thesis. Kuwait University: Department of Pathology, Faculty of Medicine, 2000.
30. Jadaon MM, Al-Otaibi MA, Easow SK, Marouf R, Al-Humood S, Das KC. The Risk of VTE Increases with Coexistence of Multiple Genetic Abnormalities. Kuwait University: The 6th Health Sciences Poster Day, Faculty of Medicine, 2001.
31. Aras O, Hanson NQ, Tsai MY, Key NS. Is homozygosity for the HR2 haplotype a risk factor for venous thromboembolism? Thromb Haemost 2002; 87: 173-4.